Show simple item record

dc.contributor.authorF. Perry, Christopher
dc.contributor.authorStevens, Maurice
dc.contributor.authorRabie, Ibrahim
dc.contributor.authorYarker, Mary-Ellen
dc.contributor.authorCochrane, Julie
dc.contributor.authorPerry, Emily
dc.contributor.authorTraficante, Robert
dc.contributor.authorComan, William
dc.date.accessioned2017-05-03T16:57:43Z
dc.date.available2017-05-03T16:57:43Z
dc.date.issued2005
dc.date.modified2009-08-30T23:14:55Z
dc.identifier.issn08864470
dc.identifier.urihttp://hdl.handle.net/10072/25457
dc.description.abstractObjective To determine whether isotretinoin (or 13-cis-retinoic acid) decreases the risk of second primary cancers in patients previously treated for cure of head and neck squamous cell carcinoma. Design Randomized, double-blind, placebo-controlled trial. Setting Two head and neck multidisciplinary cancer clinics in university teaching hospitals taking cases from 4 to 5 million people in Queensland, Australia, combined to enter appropriate patients into this trial. Patients One hundred fifty-one patients with their first head and neck squamous cell carcinoma treated with high expectation for cure and living close by. They were randomized into 3 arms to receive 3 years of treatment. Interventions Patients took isotretinoin at a high dose (1.0 mg/kg per day) or a moderate dose (0.5 mg/kg per day) or placebo. Group 1 took the high dose for 1 year and then the moderate dose for 2 years. Group 2 took the moderate dose for 3 years. Group 3 took placebo for 3 years. Main Outcome Measures The diagnosis of a second primary malignancy of the head and neck, lung, or bladder was regarded as the end point signifying failure of therapy. Issues of drug adverse effect profile and impact on survival were measured. Results There was no significant difference in the occurrence of second primary disease (P = .90), the recurrence of primary disease (P = .70), or disease-free time (P = .80) between the treatment and nontreatment arms. Numbers were too small to find differences in survival. Conclusion With evidence that retinoid treatment adversely affects survival of lung cancer and with this drug not significantly decreasing the incidence of second primary tumors of head and neck squamous cell carcinoma, the use of this drug in head and neck cancer patients for second cancer prophylaxis is not indicated.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherAmerican Medical Association
dc.publisher.placeUSA
dc.publisher.urihttp://archotol.highwire.org/cgi/content/abstract/131/3/198
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom198
dc.relation.ispartofpageto203
dc.relation.ispartofissue3
dc.relation.ispartofjournalArchives of Otolaryngology - Head & Neck Surgery
dc.relation.ispartofvolume131
dc.rights.retentionY
dc.subject.fieldofresearchCancer Therapy (excl. Chemotherapy and Radiation Therapy)
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchcode111204
dc.subject.fieldofresearchcode1103
dc.titleChemoprevention of head and neck cancer with retinoids: a negative result
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.date.issued2005
gro.hasfulltextNo Full Text
gro.griffith.authorCochrane, Julie


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record